OOIR: Observatory of International Research

Papers

(The TQCC of Diabetes Care is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2021	1635
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2022	1054
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021	702
Social Determinants of Health and Diabetes: A Scientific Review	602
2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023	548
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021	535
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022	487
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)	437
Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China	425
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022	364
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023	341
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021	328
Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?	313
Obesity Is a Risk Factor for Greater COVID-19 Severity	296
Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication	295
Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study	287
New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.	280
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022	254
The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)	239
Introduction: Standards of Medical Care in Diabetes—2022	227
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021	214
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—2021	206
6. Glycemic Targets: Standards of Care in Diabetes—2023	204
Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)	204
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Stud	191

COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Impact in Type 1 and Type 2 Diabetes	190
Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, th	189
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes	182
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening	172
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023	161
COVID-19, Hyperglycemia, and New-Onset Diabetes	160
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—2022	159
Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children?	158
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021	158
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)	158
Introduction: Standards of Medical Care in Diabetes—2021	157
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021	156
Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-	153
A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison	152
Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials	149
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study	149
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes	147
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022	146
Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspe	143
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022	143
13. Children and Adolescents: Standards of Medical Care in Diabetes—2021	141
Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters	138
Did the COVID-19 Lockdown Affect the Incidence of Pediatric Type 1 Diabetes in Germany?	136
12. Older Adults:Standards of Medical Care in Diabetes—2021	134
3. Prevention or Delay of Type 2 Diabetes:Standards of Medical Care in Diabetes—2021	129
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023	127
Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study	125
Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes	125
Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015	122
15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2021	122
15. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2022	121
Type 2 Diabetes and COVID-19–Related Mortality in the Critical Care Setting: A National Cohort Study in England, March–July 2020	119
Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study	119
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes:Standards of Medical Care in Diabetes—2022	118
Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study	114
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association	112
7. Diabetes Technology: Standards of Care in Diabetes—2023	112
Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study	111
13. Older Adults: Standards of Medical Care in Diabetes—2022	111
16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2022	110
Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy	109
Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit	107
Type 1 Diabetes and COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the U.S.	107
Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers	104
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2021	101
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes	101
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial	101
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023	100
8. Obesity Management for the Treatment of Type 2 Diabetes:Standards of Medical Care in Diabetes—2021	97
14. Children and Adolescents: Standards of Medical Care in Diabetes—2022	97

Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?	97
Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People	94
Blood Glucose Control During Lockdown for COVID-19: CGM Metrics in Italian Adults With Type 1 Diabetes	92
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial	91
Effects of Vitamin D Supplementation on Prevention of Type 2 Diabetes in Patients With Prediabetes: A Systematic Review and Meta-analysis	89
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)	88
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2022	88
Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes	87
Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies	86
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023	85
Adolescent Obesity and Early-Onset Type 2 Diabetes	85
12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022	84
Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial	82
Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19	82
Interpretable Machine Learning Framework Reveals Robust Gut Microbiome Features Associated With Type 2 Diabetes	81
Multicenter, Head-to-Head, Real-World Validation Study of Seven Automated Artificial Intelligence Diabetic Retinopathy Screening Systems	81
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023	81
Microbiota-Related Metabolites and the Risk of Type 2 Diabetes	81
Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial	79
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial	79
Association of Maternal Prepregnancy Diabetes and Gestational Diabetes Mellitus With Congenital Anomalies of the Newborn	77
Computed Tomography Highlights Increased Visceral Adiposity Associated With Critical Illness in COVID-19	76
Association of a Healthy Lifestyle With All-Cause and Cause-Specific Mortality Among Individuals With Type 2 Diabetes: A Prospective Study in UK Biobank	76
Preadmission Diabetes-Specific Risk Factors for Mortality in Hospitalized Patients With Diabetes and Coronavirus Disease 2019	76
Adult-Onset Type 1 Diabetes: Current Understanding and Challenges	75
Introduction and Methodology: Standards of Care in Diabetes—2023	74
Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolu	74
Incidence of Type 1 Diabetes in Children and Adolescents During the COVID-19 Pandemic in Germany: Results From the DPV Registry	73
Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review	73
13. Older Adults: Standards of Care in Diabetes—2023	72
Reducing Inpatient Hypoglycemia in the General Wards Using Real-time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial	71
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial	70
Diabetes Epidemiology in the COVID-19 Pandemic	69
14. Children and Adolescents: Standards of Care in Diabetes—2023	69
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases	69
Plasma Vitamin C and Type 2 Diabetes: Genome-Wide Association Study and Mendelian Randomization Analysis in European Populations	68
Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled T	68
Metabolic Syndrome and COVID-19 Mortality Among Adult Black Patients in New Orleans	66
Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET	66
Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-19 Pandemic	66
3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes—2022	65
Racial and Ethnic Disparities in Rates of Continuous Glucose Monitor Initiation and Continued Use in Children With Type 1 Diabetes	65
Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults	64
COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports	64
Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era	64
Baseline Vitamin D Status, Sleep Patterns, and the Risk of Incident Type 2 Diabetes in Data From the UK Biobank Study	64
Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy	64
Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors’ Expert Forum	63
Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non–Critically Ill Hospitalized Patients With Diabetes	63
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	62
1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes—2021	61
Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis	61
Social Determinants of Health and Structural Inequities—Root Causes of Diabetes Disparities	60
Saving the Diabetic Foot During the COVID-19 Pandemic: A Tale of Two Cities	60
Associations of Type 2 Diabetes Onset Age With Cardiovascular Disease and Mortality: The Kailuan Study	60
Retention Among Participants in the National Diabetes Prevention Program Lifestyle Change Program, 2012–2017	59
Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study	58
Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts	58
4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023	58
12. Retinopathy, Neuropathy, and Foot Care:Standards of Care in Diabetes—2023	58
16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2023	58
Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy	57
A Randomized Controlled Trial to Evaluate the Effects of a Smartphone Application–Based Lifestyle Coaching Program on Gestational Weight Gain, Glycemic Control, and Maternal and Neonatal Outcomes in W	56
Diabetic Foot Problems During the COVID-19 Pandemic in a Tertiary Care Center: The Emergency Among the Emergencies	56
Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis	56
Diagnosis of Neuropathy and Risk Factors for Corneal Nerve Loss in Type 1 and Type 2 Diabetes: A Corneal Confocal Microscopy Study	56
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial	55
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023	55
Diabetes, Glycated Hemoglobin, and the Risk of Myocardial Infarction in Women and Men: A Prospective Cohort Study of the UK Biobank	55
COVID-19 and Children With Diabetes—Updates, Unknowns, and Next Steps: First, Do No Extrapolation	55
White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries	54
Association of Maternal Folate and Vitamin B12 in Early Pregnancy With Gestational Diabetes Mellitus: A Prospective Cohort Study	54
Predicting the Risk of Inpatient Hypoglycemia With Machine Learning Using Electronic Health Records	54
Personalized Postprandial Glucose Response–Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes	54
Acrylamide Exposure and Oxidative DNA Damage, Lipid Peroxidation, and Fasting Plasma Glucose Alteration: Association and Mediation Analyses in Chinese Urban Adults	54
Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study	54
Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications	54
ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes	53
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis	53
1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2023	53

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes	53
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer	52
Racial and Socioeconomic Disparities in Pediatric Type 1 Diabetes: Time for a Paradigm Shift in Approach	52
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the D	51
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF	51
Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes	51
1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes—2022	50
Summary of Revisions: Standards of Care in Diabetes—2023	50
Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study	50
Body Weight Variability and the Risk of Cardiovascular Outcomes and Mortality in Patients With Type 2 Diabetes: A Nationwide Cohort Study	50
Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado	50
n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies	49
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88	49
A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monit	49
Remote Continuous Glucose Monitoring With a Computerized Insulin Infusion Protocol for Critically Ill Patients in a COVID-19 Medical ICU: Proof of Concept	49
Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors: A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (	49
Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D	49
Whole-Grain Processing and Glycemic Control in Type 2 Diabetes: A Randomized Crossover Trial	49
Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting	49
Gut Microbiome Composition Is Predictive of Incident Type 2 Diabetes in a Population Cohort of 5,572 Finnish Adults	49
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58	49
Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes	48
Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations	48
The Incidence of Adult-Onset Type 1 Diabetes: A Systematic Review From 32 Countries and Regions	48
Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump–Treated Type 1 Diabetes	47
Potential and Pitfalls of ChatGPT and Natural-Language Artificial Intelligence Models for Diabetes Education	47
Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic	47
Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among Individuals With Type 2 Diabetes: Results From NHANES	46
The Impact of the Stress Hyperglycemia Ratio on Short-term and Long-term Poor Prognosis in Patients With Acute Coronary Syndrome: Insight From a Large Cohort Study in Asia	46
Remote Glucose Monitoring of Hospitalized, Quarantined Patients With Diabetes and COVID-19	46
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial	46
Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes	45
Global Prevalence of Prediabetes	45
HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression	45
Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials	45
The Incidence of Diabetes Among 2,808,106 Veterans With and Without Recent SARS-CoV-2 Infection	45
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial	44
Role of Patatin-Like Phospholipase Domain–Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes	44
2022 National Standards for Diabetes Self-Management Education and Support	44
Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19	44
The Diagnosis and Management of Gestational Diabetes Mellitus in the Context of the COVID-19 Pandemic	43
Glucose Variability and Diabetic Complications: Is It Time to Treat?	43
National and State-Level Trends in Nontraumatic Lower-Extremity Amputation Among U.S. Medicare Beneficiaries With Diabetes, 2000–2017	43
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial	43
Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study	43
Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial	42
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database	42
Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up	42
Metabolic Factors, Lifestyle Habits, and Possible Polyneuropathy in Early Type 2 Diabetes: A Nationwide Study of 5,249 Patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Coh	42
Dietary Inflammatory and Insulinemic Potential and Risk of Type 2 Diabetes: Results From Three Prospective U.S. Cohort Studies	42
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes	42
Feasibility of Inpatient Continuous Glucose Monitoring During the COVID-19 Pandemic: Early Experience	41
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis	41
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100	41
Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study	41
Addendum. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S15–S33	41
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Tri	41
Decreased Incidence of Type 1 Diabetes in Young Finnish Children	41
Postpancreatitis Diabetes Confers Higher Risk for Pancreatic Cancer Than Type 2 Diabetes: Results From a Nationwide Cancer Registry	41
Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial	41
The Measurement of Insulin Clearance	41
Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease	41
Effects of a Tailored Text Messaging Intervention Among Diverse Adults With Type 2 Diabetes: Evidence From the 15-Month REACH Randomized Controlled Trial	40
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial	40
Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study	40
Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland	40
Summary of Revisions: Standards of Medical Care in Diabetes—2021	40
The Association of Fried Meat Consumption With the Gut Microbiota and Fecal Metabolites and Its Impact on Glucose Homoeostasis, Intestinal Endotoxin Levels, and Systemic Inflammation: A Randomized Con	40
Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards	40
Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews	39
Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study	39
Fasting Blood Glucose and COVID-19 Severity: Nonlinearity Matters	39
Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study	39
C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet	39
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis	39
Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes	38
Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis	38
Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting	38
Continuous Glucose Monitoring Metrics and Birth Weight: Informing Management of Type 1 Diabetes Throughout Pregnancy	38
Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19	38
Glycemic Control, Diabetic Complications, and Risk of Dementia in Patients With Diabetes: Results From a Large U.K. Cohort Study	38
The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Obj	38
Dietary Intake of Linoleic Acid, Its Concentrations, and the Risk of Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies	37
Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes	37
Comparisons of Polyexposure, Polygenic, and Clinical Risk Scores in Risk Prediction of Type 2 Diabetes	37
The Relationship Between CGM-Derived Metrics, A1C, and Risk of Hypoglycemia in Older Adults With Type 1 Diabetes	37
Continuous Positive Airway Pressure Treatment, Glycemia, and Diabetes Risk in Obstructive Sleep Apnea and Comorbid Cardiovascular Disease	37
Association of Serum Bile Acids Profile and Pathway Dysregulation With the Risk of Developing Diabetes Among Normoglycemic Chinese Adults: Findings From the 4C Study	36
Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity: Comparison of Gastric Bypass, Sleeve Gastrectomy, and Usual Care	36
Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of	36
Individual and Combined Associations of Modifiable Lifestyle and Metabolic Health Status With New-Onset Diabetes and Major Cardiovascular Events: The China Cardiometabolic Disease and Cancer Cohort (4	35
The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial	35
Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial	35
Psychosocial Moderators of the Impact of Diabetes Stigma: Results From the Second Diabetes MILES – Australia (MILES-2) Study	35
Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes	35